Literature DB >> 9002946

FLT3 ligand preserves the ability of human CD34+ progenitors to sustain long-term hematopoiesis in immune-deficient mice after ex vivo retroviral-mediated transduction.

M A Dao1, C H Hannum, D B Kohn, J A Nolta.   

Abstract

Stromal support is required during retroviral-mediated transduction of human bone marrow-derived CD34+ cells to maintain the clonogenicity of the primitive progenitors. We hypothesized that the cytokine FLT3 ligand (FL) might be able to replace the maintenance role provided by the stroma. CD34+ progenitors from human bone marrow were transduced by the retroviral vector LN with the cytokines interleukin-3 (IL-3), IL-6, and stem cell factor (SCF) present in all cultures. Transductions were performed with or without stromal support and with or without the inclusion of 100 U/mL FL. No significant increase in gene transfer into colony-forming cells was obtained by the addition of FL to the cultures. Transduction and survival of more primitive human hematopoietic cells was determined by growth in immune-deficient mice for 7 to 8 months. Human myeloid cells, T lymphocytes, and colony-forming progenitors were recovered from the marrow of mice that had received human cells transduced on stroma or in suspension culture with IL-3, IL-6, SCF, and FL, but not with IL-3, IL-6, and SCF alone. LN provirus was detected by polymerase chain reaction in the marrow recovered from 9 of 10 mice transplanted with human CD34+ cells transduced with stromal support, 5 of 11 mice that received human cells transduced in suspension culture with FL, but none of the 10 mice that received human cells transduced in suspension culture without FL We conclude that FLT3 ligand, in conjunction with IL-3, IL-6, and SCF, preserves the generative capacity of primitive human hematopoietic cells during in vitro transductions in suspension culture.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9002946

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

Review 1.  Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.

Authors:  Andre Larochelle; Cynthia E Dunbar
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

2.  Mobilization of CD34+ progenitor cells in association with decreased proliferation in the bone marrow of macaques after administration of the Fms-like tyrosine kinase 3 ligand.

Authors:  R Keith Reeves; Qing Wei; Patricia N Fultz
Journal:  Clin Vaccine Immunol       Date:  2010-06-16

3.  Reduction in levels of the cyclin-dependent kinase inhibitor p27(kip-1) coupled with transforming growth factor beta neutralization induces cell-cycle entry and increases retroviral transduction of primitive human hematopoietic cells.

Authors:  M A Dao; N Taylor; J A Nolta
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

Review 4.  Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?

Authors:  Marina Cavazzana; Emmanuelle Six; Chantal Lagresle-Peyrou; Isabelle André-Schmutz; Salima Hacein-Bey-Abina
Journal:  Hum Gene Ther       Date:  2016-02       Impact factor: 5.695

5.  The evolution of cellular deficiency in GATA2 mutation.

Authors:  Rachel E Dickinson; Paul Milne; Laura Jardine; Sasan Zandi; Sabina I Swierczek; Naomi McGovern; Sharon Cookson; Zaveyna Ferozepurwalla; Alexander Langridge; Sarah Pagan; Andrew Gennery; Tarja Heiskanen-Kosma; Sari Hämäläinen; Mikko Seppänen; Matthew Helbert; Eleni Tholouli; Eleonora Gambineri; Sigrún Reykdal; Magnús Gottfreðsson; James E Thaventhiran; Emma Morris; Gideon Hirschfield; Alex G Richter; Stephen Jolles; Chris M Bacon; Sophie Hambleton; Muzlifah Haniffa; Yenan Bryceson; Carl Allen; Josef T Prchal; John E Dick; Venetia Bigley; Matthew Collin
Journal:  Blood       Date:  2013-12-17       Impact factor: 22.113

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.